Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

55.30
-0.3500-0.63%
Volume:339.47K
Turnover:18.86M
Market Cap:9.19B
PE:-15.89
High:56.15
Open:55.71
Low:55.11
Close:55.65
52wk High:86.74
52wk Low:50.01
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.59
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:20.90
PE(LYR):-23.22

Loading ...

Ionis Pharmaceuticals Shares Sink After Late-stage Trial Failed to Meet Primary Goal

Dow Jones
·
Jul 09

U.S. Stocks on the Move-levi, Ionis Pharmaceuticals, Gloo Holdings

Reuters
·
Jul 09

S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, Bridgebio Pharma Lead

Dow Jones
·
Jul 09

Schwab Strategists Warn of a Major Market Shift: the Era of Easy Index Gains is Officially Over.

Dow Jones
·
Jul 09

Major Drugmaker Loses $27 Billion in Market Value After Failed Trial

Dow Jones
·
Jul 09

AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint

TIPRANKS
·
Jul 09

Tech Rebound Lifts European Shares After Three-day Slide

Reuters
·
Jul 09

Ionis Pharmaceuticals Shares Fall 13.8% Premarket After Drug Made in Partnership with Astrazeneca Fails Late-stage Heart Disease Trial

THOMSON REUTERS
·
Jul 09

Movement Alert|Ionis Pharmaceuticals Falls 14.75% in Pre-Market Trading, Phase 3 ATTR-CM Trial for Eplontersen Fails Primary Endpoint

Market Focus
·
Jul 09

Astrazeneca Top Loser on FTSE 100 After Heart Disease Drug Fails Late-stage Trial

Reuters
·
Jul 09

Astrazeneca Shares Set for Their Biggest One-day Fall Since March 2020

THOMSON REUTERS
·
Jul 09

Astrazeneca Shares Down 9% After Late-stage Trial Miss for Nerve Disease Drug Wainua

THOMSON REUTERS
·
Jul 09

European Shares Gain as Tech Stocks Rebound; Middle East in Focus

Reuters
·
Jul 09

Astrazeneca's Wainua Fails Key Heart Disease Trial, Shares Tumble

Reuters
·
Jul 09

Ionis Says Phase 3 Eplontersen Trial in Attr-cm Misses Primary Endpoint

Reuters
·
Jul 09

Update on Cardio-ttransform Phase 3 Trial of Eplontersen in Adults with Transthyretin-mediated Amyloid Cardiomyopathy

THOMSON REUTERS
·
Jul 09

Ionis Pharmaceuticals - Cardio-ttransform Phase 3 Trial for Eplontersen Misses Primary Endpoint up to Week 140

THOMSON REUTERS
·
Jul 09

Ionis Director Joseph Klein III Disposes of $910,231.42 in Common Shares

Reuters
·
Jul 07

Ionis Pharmaceuticals (IONS) Could Be 19% Undervalued After REVEAL Study Enrollment Milestone

Simply Wall St.
·
Jul 07

Ionis Completes Enrollment in Pivotal Phase 3 Reveal Cohort for Angelman Drug Obudanersen

Reuters
·
Jul 06